Skip to content
OP 150OP 150OP 150

Drawing based on the description in the official product monograph. No photo yet.

“150 mg tablet is a green to green/grey film-coated, oval, bi-convex tablet debossed with "OP 150" on one side and plain on the reverse”

OP 150 pill

Pill with imprint OP 150 is gray & green, oval and has been identified as Olaparib 150 mg. It is used for ovarian neoplasms. It is supplied by Astrazeneca Canada Inc.

Sold in Canada

Olaparib 150 mg

Brand
Lynparza
Imprint
OP 150
Strength
150 mg
Used for
Ovarian neoplasms
Color
Gray, Green
Shape
Oval
Form
Tablet
Manufacturer
Astrazeneca Canada Inc
Drug class
Poly(adp-ribose) polymerase inhibitor
Sold in
Canada
DIN
02475219

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Olaparib pills and guides

What is Olaparib used for?

Olaparib is used for ovarian neoplasms.

Medicine type
Poly(adp-ribose) polymerase inhibitor
Official uses from the US prescribing label

First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer

Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab

Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:

    • a deleterious or suspected deleterious BRCA mutation, and/or
    • genomic instability.

Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer

Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

Adjuvant Treatment of Germline BRCA-mutated HER2-negative High Risk Early Breast Cancer

Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

Germline BRCA-mutated HER2-negative Metastatic Breast Cancer

Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

First-Line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Adenocarcinoma

Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer

Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

Treatment of BRCA-mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone

Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

From the FDA-approved label on DailyMed (published Jul 25, 2025).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows OP 150. The parts can be split between the two sides, so turn the pill over and check both.
  • It is gray & green, oval.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Lynparza by Astrazeneca Canada Inc.

In Canada: prescription only.

Ingredients

Active: Olaparib

Other pills with imprint OP 150

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Olaparib pills